Canada's Biovail and Depomed have received Canadian regulatory approval for Glumetza for Type 2 diabetes. The companies are also expecting a decision from the FDA on Glumetza, which earned an "approvable" letter from the agency. Release [1]
Links:
[1] http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050601005480&newsLang=en